

JUL 10 2009

Application No. 10/549,893
Amendment dated: July 10, 2009

2

Docket No.: 68115(46590)

AMENDMENTS TO THE CLAIMS

Applicants respectfully request that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

1 - 22. (canceled)

23. (currently amended) A controlled release composition for oral administration, wherein

(A) a core containing (1) (+)-6-(7-hydroxy-6,7-dihydro-5Hpyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide or a salt thereof, and (2) a hydrophilic polymer selected from hydroxypropylcellulose, and low-substituted hydroxypropylcellulose, wherein an inert carrier particle is coated with a coating layer comprising (1) (+)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide or a salt thereof, and (2) a hydrophilic polymer selected from hydroxypropylcellulose, and low-substituted hydroxypropylcellulose, which is coated with

(B) a coating layer containing (1) methacrylic acid copolymers as an enteric coating agent, (2) talc as a lubricant, and (3) a plasticizer selected from polyethylene glycol and triethyl citrate, wherein the core is in a granule form having the average particle diameter of from about 50 to about 2000 μ m.

24 - 26. (canceled)

27. (previously amended) The controlled release composition according to claim 23, which is used for prevention or treatment of prostate cancer or breast cancer.

28 - 35. (canceled)

13052 745868 1